HER2-Positive Gastric Hepatoid Adenocarcinoma.
10.3904/kjm.2016.91.2.211
- Author:
Jong Kwan KIM
1
;
Jin Ho SHIN
;
Joohee LEE
;
Oh Chan KWON
;
Han Bit PARK
;
In Hwan HWANG
;
Min Hee RYU
Author Information
1. Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Publication Type:Case Report
- Keywords:
Hepatoid adenocarcinoma;
Stomach;
HER2;
Trastuzumab
- MeSH:
Adenocarcinoma*;
Biopsy;
Drug Therapy;
Follow-Up Studies;
Humans;
Korea;
Liver;
Male;
Middle Aged;
Needles;
Prognosis;
Receptor, Epidermal Growth Factor;
Stomach
- From:Korean Journal of Medicine
2016;91(2):211-215
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Gastric hepatoid adenocarcinoma is a rare adenocarcinoma that develops in the stomach. The prognosis of gastric hepatoid adenocarcinoma is poorer than that of ordinary gastric adenocarcinoma. Here, we report the first case of human epidermal growth factor receptor 2 (HER2)-positive gastric hepatoid adenocarcinoma in Korea. A 57-year-old male presented with abdominal distension and underwent endoscopic gastric biopsy and percutaneous core needle liver biopsy. The pathological findings were consistent with HER2-positive gastric hepatoid adenocarcinoma. He received six cycles of chemotherapy with cisplatin-capecitabine plus trastuzumab, which is a HER2 targeted agent. After chemotherapy, a follow-up abdominal computed tomography scan showed a partial tumor response. This case emphasizes the importance of using trastuzumab in a patient with HER2-positive gastric hepatoid adenocarcinoma.
